# DESCRIPTION

## BACKGROUND

- introduce CNS microenvironment

## SUMMARY

- provide compositions and uses
- provide kits and methods
- describe blood-CNS barrier model
- provide method for increasing blood-CNS barrier permeability
- provide method for decreasing blood-CNS barrier permeability
- describe vitronectin-integrin signaling inhibitors
- describe agents promoting vitronectin-integrin signaling
- describe FAK inhibitor for decreasing blood-CNS barrier permeability

## DETAILED DESCRIPTION

- introduce blood-CNS barrier
- describe blood-CNS barrier structure
- explain blood-CNS barrier function
- motivate need for modulating blood-CNS barrier permeability
- introduce theory of blood-CNS barrier regulation
- describe role of pericytes and astrocytes in blood-CNS barrier integrity
- introduce vitronectin and integrin in blood-CNS barrier regulation
- describe application of vitronectin-integrin signaling modulation
- summarize methods for modulating blood-CNS barrier permeability

### I. Increasing Blood-Central Nervous System (Blood-CNS) Barrier Permeability

- introduce method for increasing blood-CNS barrier permeability
- describe vitronectin-integrin signaling inhibition
- specify vitronectin secreted by CNS pericytes
- specify integrin (e.g., integrin α5) expressed on CNS endothelial cells
- describe vitronectin inhibitor
- describe inhibitory nucleic acid targeting vitronectin mRNA
- define inhibitory nucleic acid types (e.g., dsRNA, siRNA, shRNA, miRNA, amiRNA, ASOs, DNA
- describe siRNA molecule design and preparation
- specify siRNA molecule length and antisense sequence length
- describe region of complementarity in siRNA molecule
- specify siRNA molecule targeting VTN
- describe sense strand and antisense strand of siRNA molecule
- introduce antibody as vitronectin inhibitor
- describe antibody types (e.g., full-length, chimeric, humanized, Fab, F(ab′)2, Fv, scF
- describe antibody framework and constant domain
- introduce integrin inhibitor
- describe inhibitory nucleic acid targeting ITGA5
- define shRNA molecule length
- define sense sequence length
- describe shRNA molecule targeting ITGA5 mRNA
- describe region of complementarity
- describe shRNA molecule identical to SEQ ID NOs: 3 or 4
- describe integrin α5 inhibitor as antibody
- describe administration methods
- describe RGD peptide as integrin α5 inhibitor
- describe small molecule integrin α5 inhibitor
- describe non-peptidic RGD mimetic
- describe effective amount of inhibitor
- describe inhibition of vitronectin-integrin signaling
- describe administration of inhibitor to treat CNS disease
- describe diagnosis of CNS disease
- describe alleviating symptoms of CNS disease
- describe administration of inhibitor with therapeutic agent
- describe characteristics of therapeutic agent

### II. Decreasing Blood-CNS Barrier Permeability

- introduce method for decreasing blood-CNS barrier permeability
- promote vitronectin-integrin signaling at blood-CNS barrier
- describe recombinant vitronectin or fragment as agent
- specify human vitronectin amino acid sequence
- describe recombinant mouse vitronectin or fragment as agent
- specify mouse vitronectin amino acid sequence
- describe nucleic acid encoding vitronectin as agent
- specify human vitronectin mRNA sequence
- specify mouse vitronectin mRNA sequence
- describe nucleic acid encoding integrin α5 as agent
- specify human integrin α5 mRNA sequence
- specify mouse integrin α5 mRNA sequence
- describe administration methods for agents
- discuss treatment of diseases associated with endothelial cell dysfunction

### III. Blood-CNS Model

- introduce blood-CNS model
- describe blood-CNS model with endothelial cells and vitronectin
- describe blood-CNS model with endothelial cells and cells secreting vitronectin
- specify pericytes as cells secreting vitronectin
- describe in vitro blood-CNS barrier models
- discuss development of blood-CNS barrier model from stem cell sources

## EXAMPLES

### Example I. Pericyte-to-Endothelial Cell Signaling via Vitronectin-Integrin Regulates Blood-CNS Barrier

- introduce blood-CNS barriers
- motivate importance of blood-CNS barriers
- summarize current understanding of blood-CNS barriers
- introduce pericytes as regulators of blood-CNS barriers
- identify vitronectin as a pericyte-secreted ECM protein
- establish vitronectin as a regulator of blood-CNS barrier function
- show vitronectin expression in CNS pericytes
- demonstrate vitronectin requirement for blood-CNS barrier integrity
- rule out plasma vitronectin as essential for barrier function
- show vitronectin regulates blood-CNS barrier function by suppressing transcytosis
- demonstrate normal vessel patterning and pericyte coverage in Vtn-/- mice
- rule out ECM changes as cause of barrier defects in Vtn-/- mice
- introduce vitronectin binding to integrin receptors as regulator of barrier function
- demonstrate VtnRGE mice phenocopy Vtn-/- mice
- conclude vitronectin binding to integrin receptors induces and maintains barrier function
- introduce vitronectin-integrin α5 signaling
- demonstrate α5 adhesions in CNS endothelial cells
- investigate role of vitronectin-integrin α5 in vesicular trafficking
- identify endothelial integrin receptors in vivo
- determine role of Itga5 and Itgav in barrier function
- ablate Itga5 and Itgav genes in endothelial cells
- examine barrier function in Itga5fl/fl;Cdh5-CreER and Itgavfl/fl;Cdh5-CreER mice
- perform genetic rescue experiment with Vtn−/− and Cav-1−/− mice
- describe material and methods for mouse experiments
- outline immunohistochemistry protocol
- describe fluorescent in situ hybridization and barrier permeability assays
- introduce in vivo siRNA experiments
- describe siRNA complex formation and injection
- outline plasma isolation and ELISA for vitronectin knockdown
- detail transmission electron microscopy protocol
- describe Western blotting protocol
- outline cell culture media and coverslip coating
- describe imaging focal adhesions in cell culture
- detail in vitro shRNA and endocytosis experiments
- describe imaging protocols
- outline quantification and statistical analysis
- describe fluorescent in situ hybridization
- detail leakage assays
- outline ELISA for vitronectin protein expression levels
- describe vesicular density from EM data
- detail vessel density, branching, and radial outgrowth
- outline pericyte density, coverage, and astrocyte endfeet coverage

### Example II. FAK Inhibitor Maintains Blood-CNS Barrier Integrity in Vtn−/− Mice

- describe PF-562,271 experiment

## OTHER EMBODIMENTS

- describe alternative features and modifications

### EQUIVALENTS AND SCOPE

- describe use of articles such as “a,” “an,” and “the”
- describe use of “or” between group members
- describe variations, combinations, and permutations of claim limitations

